Recent Progress in GM-CSF-Based Cancer Immunotherapy
2017; Future Medicine; Volume: 9; Issue: 4 Linguagem: Inglês
10.2217/imt-2016-0141
ISSN1750-7448
AutoresWan-Lun Yan, Kuan‐Yin Shen, Chun-Yuan Tien, Yuan Chen, Shih‐Jen Liu,
Tópico(s)RNA Interference and Gene Delivery
ResumoCancer immunotherapy is a growing field. GM-CSF, a potent cytokine promoting the differentiation of myeloid cells, can also be used as an immunostimulatory adjuvant to elicit antitumor immunity. Additionally, GM-CSF is essential for the differentiation of dendritic cells, which are responsible for processing and presenting tumor antigens for the priming of antitumor cytotoxic T lymphocytes. Some strategies have been developed for GM-CSF-based cancer immunotherapy in clinical practice: GM-CSF monotherapy, GM-CSF-secreting cancer cell vaccines, GM-CSF-fused tumor-associated antigen protein-based vaccines, GM-CSF-based DNA vaccines and GM-CSF combination therapy. GM-CSF also contributes to the regulation of immunosuppression in the tumor microenvironment. This review provides recommendations regarding GM-CSF-based cancer immunotherapy.
Referência(s)